Treatment of Kaposi's sarcoma in resource-poor settings [2]

Tropical Doctor

Volumn 35, Issue 1, 2005, Pages 60-

  Dedicoat, Martin ^a,b   Newton, R ^c  

^a Hlabisa Hospital   (South Africa)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; CANCER INCIDENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LETTER; SOCIOECONOMICS; WORLD HEALTH ORGANIZATION;

AFRICA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; SARCOMA, KAPOSI; SKIN NEOPLASMS; SOCIOECONOMIC FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 13244295462     PISSN: 00494755     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Dedicoat M, Newton R. A review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. Br J Cancer 2003;88:1-3
2. Parkin DM, Ferlay J, Hamdi-Chérif M, et al. (eds) Cancer in Africa: Epidemiology and Prevention, Vol 153. Lyon: IARC Press, 2003:286-94
3. Dedicoat M, Vaithilingum M, Newton R. The treatment of Kaposi's sarcoma in HIV-1 infected individuals with an emphasis on resource poor settings. Cochrane Database Syst Rev 2003;issue 3
4. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002;31:384-90